These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 17697911

  • 1. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T.
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
    Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.
    Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
    [Abstract] [Full Text] [Related]

  • 3. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
    Bott S, Tusek C, Heinemann L, Friberg HH, Heise T.
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
    [Abstract] [Full Text] [Related]

  • 4. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
    Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS.
    Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
    [Abstract] [Full Text] [Related]

  • 5. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
    Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H.
    Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S, Kidron M, Wohlgelernter J, Raz I.
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR.
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.